Loading stock data…
Instil Bio (TIL)
$7.61+0.18 (+2.42%)
Market OpenUpdated 2:56 PM EDT
Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Instil Bio, Inc. in the Healthcare sector is trading at $7.61 with a market capitalization of $53M. Wall Street consensus targets $7.00 (1 analysts), implying a -8.0% move over the next 12 months. The stock is currently near its 52-week low of $5.67, remaining 31.4% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 29 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply -8.0% downside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 29) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$6.02M↑ | -$9.56M↑ | -$15.02M↓ | -$12.90M↑ | -$14.48M |
| Net Income | -$4.20M↑ | -$8.19M↑ | -$13.59M↑ | -$21.39M↑ | -$28.20M |
Peer Comparison
JNJUNHPFE
Fundamentals
Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Inst...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$52.71M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-42.80%
Volume
Today's trading volume
11,331
Recent News
CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a Turnaround
CarMax runs a nationwide network of used car stores and digital channels, offering multi-channel sales and financing to U.S. consumers.
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.
This clinical-stage biotech develops therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition.
Instil Bio, Inc. (NASDAQ:TIL) is definitely on the radar of institutional investors who own 36% of the company
NasdaqCM:TIL 1 Year Share Price vs Fair Value Explore Instil Bio's Fair Values from the Community and select yours Key...